New clinical data in interventional treatments for aortic and peripheral vascular diseases have been revealed by Medtronic during a late-breaking trial session at Vascular Interventional Advances (VIVA) 2015.
The first patient has been enrolled in the US ROADSTER 2 post approval study at Greenville Memorial Hospital in Greenville, USA.
Endologix and TriVascular announced on 26 October that they have entered into a definitive merger agreement under which Endologix and TriVascular will combine in a stock and cash transaction. The transaction is valued at US$9.10 per TriVascular share, or a total of approximately US$211 million, based on Endologix’s closing stock price of US$13.81 per share on 23 October 2015.
It is safe and effective to place biodegradable biliary stents to treat benign biliary strictures. This treatment compares favourably with standard techniques in terms of patients’ quality of life and avoids the need for repeated invasive procedures, found a study recently presented at the CIRSE conference (26–30 September, Lisbon, Portugal).
Merit has announced that it has signed an exclusive worldwide distribution agreement (excluding Japan) with Sumitomo Bakelite to distribute a steerable microcatheter under the proposed trademark of Swiftninja.
Bob Abraham, ABK Biomedical, Halifax, Canada, presented computed tomography and magnetic resonance imaging characteristics of novel radiopaque yttrium-strontium-gallium–silicate oxide glass microspheres at CIRSE. These beads, called Occlu90Y, are potential materials for radioembolization.
The presentation of the 12-month results from the Lutonix Global Real-World Registry at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 meeting has been announced by C. R. Bard, just months after publication of the 1-year data from the Lutonix 035 Drug Coated Balloon (DCB) Catheter pivotal, randomised Levant 2 trial in the New England Journal of Medicine.
Silk Road Medical has announced the receipt of up to US$57 million investment in the form of equity and debt funding from new and existing investors. CRG joins Warburg Pincus and The Vertical Group as an equity investor, and has led the debt financing.
Bolton Medical has announced the first commercial implant of the Treo abdominal stent graft system. Theodosios Bisdas and Giovanni Torsello (St Franciscus Hospital Muenster in Munster, Germany) performed this first procedure, the company reported.
The IN.PACT Admiral drug-coated balloon (DCB) provides superior clinical outcomes at two years compared to standard balloon angioplasty for the interventional treatment of peripheral arterial disease in the superficial femoral arteries and/or popliteal arteries.
The first two cases in the EffPac randomised clinical multicentre trial of its luminor 35 drug-eluting balloon system have been successfully performed, according to iVascular.
Riccardo Lencioni joined Sylvester Comprehensive Cancer Center, Miami, USA, as director of Interventional Oncology Research from the University of Pisa in Italy, where he was a professor at the School of Medicine. Lencioni is an accomplished interventional oncologist, particularly well-known for his influential work on liver cancer.
BTG and Mirada, a medical imaging software company, have announced an important collaboration to develop dosimetry software solutions to optimise radioembolization therapy with TheraSphere.
The as-yet unpublished, five-year outcome after catheter-directed thrombolysis for upper femoral and/or iliac vein thrombosis, as determined from the randomised, controlled trial, the CaVenT study, were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) meeting (26–30 September, Lisbon, Portugal).
Jim Reekers, Amsterdam, The Netherlands, delivering the Josef Roesch honorary lecture at CIRSE 2015 (26–30 September, Lisbon, Portugal), urged delegates to look at new definitions for critical limb ischaemia and pointed to the potential of perfusion angiography in predicting the outcome of endovascular intervention. “Look past the re-opening of vessels alone,” he said.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos